{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:51:46Z","timestamp":1788274306648,"version":"build-2803163510"},"reference-count":234,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Prostate cancer is one of the most common malignancies in men, and advanced or metastatic disease remains associated with substantial morbidity and mortality. Therapeutic progress in recent years has been driven by the introduction of targeted treatment strategies, notably poly (ADP-ribose) polymerase (PARP) inhibitors, prostate-specific membrane antigen (PSMA)\u2013directed radioligand therapy (RLT), and androgen receptor pathway inhibitors (ARPIs). This review summarizes evidence from phase II and III clinical trials, meta-analyses, and real-world studies evaluating the efficacy, safety, and clinical integration of olaparib, lutetium (177Lu) vipivotide tetraxetan, and abiraterone in advanced prostate cancer. Emphasis is placed on the practical clinical application of these agents, including patient selection, treatment sequencing, and combination strategies. PARP inhibition with olaparib has demonstrated clear benefits in metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) mutations, particularly BRCA1\/2 alterations. PSMA-directed RLT offers a survival advantage in PSMA-positive mCRPC following AR pathway inhibition, with distinct toxicity considerations that influence patient selection. Abiraterone remains a cornerstone therapy across disease stages and plays an important role both as monotherapy and as a combination partner. Emerging data suggest a potential synergy between PARP inhibitors and AR-targeted agents, while also highlighting the limitations of biomarker-unselected approaches. We conclude that the optimal use of PARP inhibitors, PSMA-targeted RLT, and ARPIs requires a personalized strategy guided by molecular profiling, functional imaging, prior treatment exposure, and safety considerations. This clinically focused overview aims to support evidence-based decision-making in an increasingly complex treatment landscape.<\/jats:p>","DOI":"10.3390\/jcm15020685","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T15:47:37Z","timestamp":1768405657000},"page":"685","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Emerging Therapeutic Strategies in Prostate Cancer: Targeted Approaches Using PARP Inhibition, PSMA-Directed Therapy, and Androgen Receptor Blockade with Olaparib, Lutetium (177Lu)Vipivotide Tetraxetan, and Abiraterone"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3902-2744","authenticated-orcid":false,"given":"Piotr","family":"Kawczak","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Gda\u0144sk, 80-416 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6468-1974","authenticated-orcid":false,"given":"Tomasz","family":"B\u0105czek","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Gda\u0144sk, 80-416 Gda\u0144sk, Poland"},{"name":"Department of Nursing and Medical Rescue, Institute of Health Sciences, Pomeranian University in S\u0142upsk, 76-200 S\u0142upsk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"12","article-title":"Cancer Statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","article-title":"Prostate cancer","volume":"398","author":"Sandhu","year":"2021","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging Mechanisms of Resistance to Androgen Receptor Inhibitors in Prostate Cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_5","first-page":"PO.17.00029","article-title":"Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making","volume":"2017","author":"Abida","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"67S","DOI":"10.2967\/jnumed.116.186767","article-title":"Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy","volume":"58","author":"Eiber","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/CU9.0000000000000300","article-title":"The Interconnection between Androgen Receptor and DNA Damage Response Pathways in Prostate Cancer","volume":"19","author":"Sands","year":"2025","journal-title":"Curr. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000455160","article-title":"Cancer Stem Cells in Prostate Cancer: Implications for Targeted Therapy","volume":"99","author":"Domingos","year":"2017","journal-title":"Urol. Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/annonc\/mdz270","article-title":"Advances in Targeted Alpha Therapy for Prostate Cancer","volume":"30","author":"Gerritsen","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/14737140.2020.1814151","article-title":"The Potential of PSMA-Targeted Alpha Therapy in the Management of Prostate Cancer","volume":"20","author":"Filippi","year":"2020","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate Cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"382","author":"Mateo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Gene Aberrations (TOPARP-B): A Multicentre, Open-Label, Randomised, Phase 2 Trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/pros.24788","article-title":"A Panel-Based Mutational Signature of Homologous Recombination Deficiency Associates with Response to PARP Inhibition in Metastatic Castration-Resistant Prostate Cancer","volume":"84","author":"Boiarsky","year":"2024","journal-title":"Prostate"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00345-024-05188-7","article-title":"Real-World Data on the Prevalence of BRCA1\/2 and HRR Gene Mutations in Patients with Primary and Metastatic Castration Resistant Prostate Cancer","volume":"42","author":"Hommerding","year":"2024","journal-title":"World J. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"17588359231221337","DOI":"10.1177\/17588359231221337","article-title":"Development of PARP Inhibitors in Advanced Prostate Cancer","volume":"16","author":"Bourlon","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-Blind, Phase 3 Trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.euo.2025.04.012","article-title":"Niraparib and Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial","volume":"8","author":"Chi","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Armstrong, A.J., Saad, F., Oya, M., Vianna, K., \u00d6zg\u00fcro\u011flu, M., Gedye, C., Buchschacher, G.L., Lee, J.Y., Emmenegger, U., and Navr\u00e1til, J. (2025). Patient-Reported Outcomes for Men with Metastatic Castration-Resistant Prostate Cancer Who Received Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the Phase 3 PROpel Study. Eur. Urol. Oncol.","DOI":"10.1016\/j.euo.2025.09.010"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 Versus Cabazitaxel in Patients with Metastatic Castration-Resistant Prostate Cancer (TheraP): A Randomised, Open-Label, Phase 2 Trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2967\/jnumed.119.236414","article-title":"Long-Term Follow-Up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer","volume":"61","author":"Violet","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s12032-024-02466-7","article-title":"Therapeutic Response and Safety of Radioligand Therapy with 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients","volume":"41","author":"Ashfaq","year":"2024","journal-title":"Med. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1055\/s-0044-1779634","article-title":"Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [177Lu]Lu-PSMA-617 Radioligand Therapy","volume":"34","author":"Siripongsatian","year":"2024","journal-title":"Indian J. Radiol. Imaging"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and Increased Survival in Metastatic Prostate Cancer","volume":"364","author":"Logothetis","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone Plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy","volume":"377","author":"James","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","article-title":"Abiraterone Acetate Plus Prednisolone with or without Enzalutamide for Patients with Metastatic Prostate Cancer Starting Androgen Deprivation Therapy: Final Results from Two Randomised Phase 3 Trials of the STAMPEDE Platform Protocol","volume":"24","author":"Attard","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40265-024-02071-y","article-title":"Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer","volume":"84","author":"Kostos","year":"2024","journal-title":"Drugs"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e2423186","DOI":"10.1001\/jamanetworkopen.2024.23186","article-title":"Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers","volume":"7","author":"Jo","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1007\/s00259-025-07083-8","article-title":"The Role of PSMA-Based Radioligand Therapy in Hormone-Sensitive Prostate Cancer","volume":"52","author":"Laudicella","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41391-024-00906-z","article-title":"Navigating Therapeutic Sequencing in the Metastatic Castration-Resistant Prostate Cancer Patient Journey","volume":"28","author":"McManus","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.urology.2005.03.044","article-title":"Multidisciplinary Management of Advanced Prostate Cancer: Changing Perspectives on Referring Patients and Enhancing Collaboration between Oncologists and Urologists in Clinical Trials","volume":"65","author":"Carducci","year":"2005","journal-title":"Urology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e531","DOI":"10.1016\/S1470-2045(24)00439-X","article-title":"PSMA-PET Research: Addressing Challenges and Prospects","volume":"25","author":"Hu","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Rose, M., Burgess, J.T., O\u2019Byrne, K., Richard, D.J., and Bolderson, E. (2020). PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.564601"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.2217\/fon-2020-1245","article-title":"Olaparib for the Treatment of Metastatic Prostate Cancer","volume":"17","author":"Dror","year":"2021","journal-title":"Future Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s11255-023-03487-3","article-title":"Recent Advances in the Molecular Targeted Drugs for Prostate Cancer","volume":"55","author":"Gao","year":"2023","journal-title":"Int. Urol. Nephrol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1007\/s12672-025-03893-2","article-title":"Unveiling Oncogene-Induced Senescence: A New Frontier in Prostate Cancer Prognosis and Therapy","volume":"16","author":"Peng","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Rahman, M., Akter, K., Ahmed, K.R., Fahim, M.M.H., Aktary, N., Park, M.N., Shin, S.W., and Kim, B. (2024). Synergistic Strategies for Castration-Resistant Prostate Cancer: Targeting AR-V7, Exploring Natural Compounds, and Optimizing FDA-Approved Therapies. Cancers, 16.","DOI":"10.3390\/cancers16162777"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.seminoncol.2023.09.005","article-title":"PARP Inhibitors: A Review of the Pharmacology, Pharmacokinetics, and Pharmacogenetics","volume":"51","author":"Zeng","year":"2024","journal-title":"Semin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","article-title":"Olaparib Combined with Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial","volume":"19","author":"Clarke","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1200\/JCO-24-02834","article-title":"Overall Survival and the Evolving Benefit\u2013Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer","volume":"43","author":"Shah","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Giudice, E., Gentile, M., Salutari, V., Ricci, C., Musacchio, L., Carbone, M.V., Ghizzoni, V., Camarda, F., Tronconi, F., and Nero, C. (2022). PARP Inhibitors Resistance: Mechanisms and Perspectives. Cancers, 14.","DOI":"10.3390\/cancers14061420"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Apelian, S., Martincuks, A., Whittum, M., Yasukawa, M., Nguy, L., Mathyk, B., Andikyan, V., Anderson, M.L., Rutherford, T., and Cristea, M. (2025). PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence, and Evolving Strategies. Biomedicines, 13.","DOI":"10.3390\/biomedicines13051126"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","article-title":"Mechanisms of PARP Inhibitor Sensitivity and Resistance","volume":"71","year":"2018","journal-title":"DNA Repair"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1007\/s12325-024-02844-7","article-title":"Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value","volume":"41","author":"Fan","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.23.00339","article-title":"Olaparib for the Treatment of Patients with Meta-static Castration-Resistant Prostate Cancer and Alterations in BRCA1 and\/or BRCA2 in the PROfound Trial","volume":"42","author":"Mateo","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/j.ccell.2024.10.015","article-title":"Elucidating Acquired PARP Inhibitor Resistance in Advanced Prostate Cancer","volume":"42","author":"Seed","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Raval, A.D., Queen, V., Korn, M.J., Quintero, V., and Freedland, S.J. (2025). Real-World Treatment Patterns and Survival in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review of Observational Studies. Eur. Urol. Focus, online ahead of print.","DOI":"10.1016\/j.euf.2025.10.011"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Saad, F., Armstrong, A.J., Oya, M., Shore, N., Procopio, G., Guedes, J.D., Arslan, C., Mehra, N., Brown, E., and Joung, J.Y. (2025). Prostate-Specific Antigen and Objective Response Analyses in PROpel: Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone as First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer. Eur. Urol. Oncol., in press.","DOI":"10.1016\/j.euo.2025.10.010"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Piombino, C., Pipitone, S., Tonni, E., Mastrodomenico, L., Oltrecolli, M., Tchawa, C., Matranga, R., Roccabruna, S., D\u2019Agostino, E., and Pirola, M. (2024). Homologous Recombination Repair Deficiency in Metastatic Prostate Cancer: New Therapeutic Opportunities. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25094624"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"102411","DOI":"10.1016\/j.clgc.2025.102411","article-title":"Impact of HRR Gene Subclass on Clinical Outcomes of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer","volume":"23","author":"Dimitrov","year":"2025","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"EVIDoa2200043","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s00335-025-10134-y","article-title":"Identification of Novel Gene Expression Patterns and Pathways Involved in PARP-1 Inhibitor Resistance","volume":"36","author":"Khan","year":"2025","journal-title":"Mamm. Genome"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1158\/1078-0432.CCR-24-1402","article-title":"Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)","volume":"30","author":"Hussain","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11523-025-01146-4","article-title":"Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation","volume":"20","author":"Saad","year":"2025","journal-title":"Target Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41416-023-02326-7","article-title":"PARP Inhibitors: Enhancing Efficacy through Rational Combinations","volume":"129","author":"Bhamidipati","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.euo.2023.08.004","article-title":"Practical Guidance on Es-tablishing a Molecular Testing Pathway for Alterations in Homologous Recombination Repair Genes in Clinical Practice for Patients with Metastatic Prostate Cancer","volume":"7","author":"Schostak","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1158\/1078-0432.CCR-21-3940","article-title":"Tumor Genomic Testing for >4000 Men with Metastatic Castration-Resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)","volume":"28","author":"Hussain","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in Relapsed, Platinum-Sensitive High-Grade Ovarian Carcinoma (ARIEL2 Part 1): An International, Multicentre, Open-Label, Phase 2 Trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_67","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH) (2025, December 04). Olaparib (Lynparza): CADTH Reimbursement Recommendation: Indication: In Combination with Abiraterone and Prednisone or Prednisolone for the Treatment of Adult Patients with Deleterious or Suspected Deleterious Germline and\/or Somatic BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC) in Whom Chemotherapy Is Not Clinically Indicated; BRCA Mutation Must Be Confirmed before Olaparib Treatment Is Initiated; Report No. PC0319REC; CADTH: Ottawa, ON, Canada, 2024, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK602511\/."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1634\/theoncologist.2017-0485","article-title":"Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations","volume":"23","author":"Moore","year":"2018","journal-title":"Oncologist"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2217\/fon.14.313","article-title":"Olaparib: An Oral PARP-1 and PARP-2 Inhibitor with Promising Activity in Ovarian Cancer","volume":"11","author":"Gunderson","year":"2015","journal-title":"Future Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"19895","DOI":"10.1038\/s41598-024-70398-3","article-title":"Low-Dose Abiraterone Plus Olaparib as a Late-Line Treatment for mCRPC Patients with-out BRCA1\/2 Mutations: A Multicenter Retrospective Pilot Study","volume":"14","author":"Chen","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN Guidelines\u00ae Insights: Prostate Cancer, Version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib Tablets as Maintenance Therapy in Patients with Platinum-Sensitive, Relapsed Ovarian Cancer and a BRCA1\/2 Mutation (SOLO2\/ENGOT-Ov21): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial","volume":"18","author":"Ledermann","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_76","unstructured":"European Medicines Agency (2025, December 01). Lynparza: Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lynparza."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","article-title":"Olaparib Combined with Chemotherapy for Recurrent Platinum-Sensitive Ovarian Cancer: A Randomised Phase 2 Trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_78","unstructured":"U.S. Food and Drug Administration (2025, December 01). Lynparza (Olaparib) Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/208558s014lbl.pdf."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and Comparing Adverse Events between PARP Inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic Syndrome and Acute Myeloid Leukaemia in Patients Treated with PARP Inhibitors: A Safety Meta-Analysis of Randomised Controlled Trials and a Retrospective Study of the WHO Pharmacovigilance Database","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40291-022-00594-2","article-title":"Lutetium Lu 177 Vipivotide Tetraxetan: First Approval","volume":"26","author":"Keam","year":"2022","journal-title":"Mol. Diagn. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","article-title":"FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer","volume":"29","author":"Fallah","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1053\/j.semnuclmed.2024.02.007","article-title":"Prostate Cancer Theranostics with [177Lu]-PSMA","volume":"54","author":"Ahmadzadehfar","year":"2024","journal-title":"Semin. Nucl. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.3390\/curroncol31030106","article-title":"177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice","volume":"31","author":"Chi","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s11912-025-01686-y","article-title":"Prostate Cancer Radioligand Therapy: PSMA and Beyond, Current Landscape and Future Directions","volume":"27","author":"Bent","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Zhang, H., Koumna, S., Pouliot, F., Beauregard, J.M., and Kolinsky, M. (2021). PSMA Theranostics: Current Landscape and Future Outlook. Cancers, 13.","DOI":"10.3390\/cancers13164023"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e15734056362468","DOI":"10.2174\/0115734056362468250709045212","article-title":"A Case Report on the Dramatic Response of [177Lu]-PSMA Therapy for Metastatic Prostate Cancer","volume":"21","author":"Erdogan","year":"2025","journal-title":"Curr. Med. Imaging"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Palihati, M., Das, J.P., Yeh, R., and Capaccione, K. (2025). Emerging PET Imaging Agents and Targeted Radioligand Therapy: A Review of Clinical Applications and Trials. Tomography, 11.","DOI":"10.3390\/tomography11080083"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.2967\/jnumed.124.267452","article-title":"Dosimetry of [177Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Meta-Analysis","volume":"65","author":"Ells","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to Predict Outcomes after [177Lu]-PSMA Therapy in Men with Metastatic Castration-Resistant Prostate Cancer: An International, Multicentre, Retrospective Study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"17588359221081922","DOI":"10.1177\/17588359221081922","article-title":"Biomarkers to Personalize Treatment with 177Lu-PSMA-617 in Men with Metastatic Castration-Resistant Prostate Cancer\u2014A State of the Art Review","volume":"14","author":"Heidegger","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1358\/dot.2023.59.1.3476574","article-title":"Lutetium Lu 177 Vipivotide Tetraxetan for Prostate Cancer","volume":"59","author":"Liu","year":"2023","journal-title":"Drugs Today"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.euo.2023.07.018","article-title":"Real-World Outcomes and Predictive Biomarkers for 177Lutetium Prostate-Specific Membrane Antigen Ligand Treatment in Metastatic Castration-Resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-Institutional Observational Study","volume":"7","author":"Kafka","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"ref_95","unstructured":"(2025, December 02). Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto). Canadian Journal of Health Technologies CADTH Reimbursement Review. Available online: https:\/\/www.cda-amc.ca\/sites\/default\/files\/DRR\/2023\/PC0297-Pluvicto_combined.pdf."},{"key":"ref_96","unstructured":"U.S. Food and Drug Administration (2026, January 10). FDA Approves Pluvicto for Metastatic Castration-Resistant Prostate Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1053\/j.semnuclmed.2023.06.007","article-title":"Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer","volume":"53","author":"Alati","year":"2023","journal-title":"Semin. Nucl. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e233460","DOI":"10.1148\/radiol.233460","article-title":"Quantitative [68Ga]-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Following [177Lu]-PSMA-617 (VISION Trial)","volume":"312","author":"Kuo","year":"2024","journal-title":"Radiology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.eururo.2024.08.021","article-title":"Association of Declining Prostate-Specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial","volume":"86","author":"Armstrong","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/oncolo\/oyac279","article-title":"PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials","volume":"28","author":"Ramnaraign","year":"2023","journal-title":"Oncologist"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3390\/curroncol31020078","article-title":"Contemporary Systemic Therapy Intensification for Prostate Cancer: A Review for General Practitioners in Oncology","volume":"31","author":"Batra","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.7150\/thno.92612","article-title":"PSMA-Targeted Radiotheranostics in Modern Nuclear Medicine: Then, Now, and What of the Future?","volume":"14","author":"Sallam","year":"2024","journal-title":"Theranostics"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a Change of Androgen Receptor Pathway Inhibitor Therapy for Taxane-Naive Patients with Progressive Metastatic Castration-Resistant Prostate Cancer (PSMAfore)","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"ref_104","unstructured":"U.S. Food and Drug Administration (2026, January 10). FDA Expands Pluvicto\u2019s Metastatic Castration-Resistant Prostate Cancer Indication, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication."},{"key":"ref_105","unstructured":"Eropean Medicines Agency (EMA) (2025, December 02). Pluvicto, INN-Lutetium (177Lu) Vipivotide Tetraxetan. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/rmp\/pluvicto-epar-risk-management-plan_en.pdf."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Ninatti, G., Lee, S.T., and Scott, A.M. (2025). Radioligand Therapy in Cancer Management: A Global Perspective. Cancers, 17.","DOI":"10.3390\/cancers17213412"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Morrison, G., and Holle, L.M. (2025). Lutetium Lu 177 Vipivotide Tetraxetan: A Literature Review. J. Oncol. Pharm. Pract., online ahead of print.","DOI":"10.1177\/10781552251392083"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1007\/s00259-025-07125-1","article-title":"Impact of Extended [177Lu] Lu-PSMA-617 Therapy on Absorbed Kidney Dose and CKD-EPI Values: How Long Can Therapy Be Safely Continued?","volume":"52","author":"Topal","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/j.semnuclmed.2021.11.003","article-title":"Radiation Dosimetry in 177Lu-PSMA-617 Therapy","volume":"52","author":"Jackson","year":"2022","journal-title":"Semin. Nucl. Med."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Shamshirgaran, A., Sahafi, P., Samadi, M.H., Saeed, M., Mohammadzadeh Kosari, H., Erfani, S., Pirayesh, E., Aryana, K., Harsini, S., and Askari, E. (2025). Efficacy and Safety of Lutetium-177 (177Lu)-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients with Superscan Pattern: A Retrospective Cohort Study. Ann. Nucl. Med., 39.","DOI":"10.1007\/s12149-025-02127-3"},{"key":"ref_111","unstructured":"Food and Drug Administration (FDA) (2025, December 02). PLUVICTO (Lutetium Lu 177 Vipivotide Tetraxetan), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215833s000lbl.pdf."},{"key":"ref_112","unstructured":"National Library of Medicine, and NIH (2025, December 02). Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto), Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK596311\/."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1007\/s00259-025-07200-7","article-title":"Impact of Baseline [18F]-Flotufolastat PET Bone Tumor Volume for Prognosticating Severe Hematologic Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving [177Lu]-PSMA-Targeted Radioligand Therapy","volume":"52","author":"Karimzadeh","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1055\/a-2654-4048","article-title":"Overview of Selected Completed Prospective Studies on PSMA-Targeted Radioligand Therapy with [177Lu]Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer","volume":"64","author":"Karimzadeh","year":"2025","journal-title":"Nuklearmedizin"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the Use of Next-Generation Sequencing (NGS) for Patients with Advanced Cancer in 2024: A Report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1007\/s00259-025-07103-7","article-title":"Radiotheranostic Landscape: A Review of Clinical and Preclinical Development","volume":"52","author":"Tran","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Parent, E.E., and Kase, A.M. (2022). A Treatment Paradigm Shift: Targeted Radionuclide Therapies for Metastatic Castrate Resistant Prostate Cancer. Cancers, 14.","DOI":"10.20944\/preprints202208.0071.v1"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Neagu, M., Constantin, C., Hinescu, M.E., Bleotu, P.G., Popovici, M.G., Zai, M.I., and Spohr, K.M. (2025). Radionuclides Landscape in Prostate Cancer Theranostics. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26146751"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1053\/j.semnuclmed.2024.05.011","article-title":"Combination Strategies and Targeted Radionuclide Therapies","volume":"54","author":"Jewell","year":"2024","journal-title":"Semin. Nucl. Med."},{"key":"ref_120","first-page":"744","article-title":"Prognostic Factors of PSMA-Targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis","volume":"28","author":"Yanagisawa","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"20972","DOI":"10.1021\/acs.jmedchem.5c01593","article-title":"How a Medicinal Chemistry Project Changed the Way Prostate Cancer Is Diagnosed and Treated","volume":"68","author":"Kozikowski","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e597","DOI":"10.1016\/j.prro.2025.03.010","article-title":"Combination Metastasis-Targeted External Beam Radiation Therapy with [177Lu]-PSMA-617 in Patients with Advanced Castration-Resistant Prostate Cancer","volume":"15","author":"Mohammadi","year":"2025","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2340\/1651-226X.2025.44748","article-title":"Real-World Outcomes of 177Lu-PSMA-I&T in Metastatic Castration-Resistant Prostate Cancer: The KuPSMALu Trial in Eastern Finland","volume":"64","author":"Poutiainen","year":"2025","journal-title":"Acta Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1007\/s00259-025-07280-5","article-title":"Genomic Instability Is Associated with Response to [177Lu]Lu-PSMA-I&T Radioligand Therapy: An Exploratory, Preliminary Liquid Biopsy Analysis","volume":"52","author":"Kluge","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.2967\/jnumed.124.268363","article-title":"Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy","volume":"65","author":"Calais","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"102748","DOI":"10.1016\/j.ctrv.2024.102748","article-title":"Salivary Toxicity from PSMA-Targeted Radiopharmaceuticals: What We Have Learned and Where We Are Going","volume":"127","author":"Muniz","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"101445","DOI":"10.1016\/j.tranon.2022.101445","article-title":"Assessment of Salivary Gland Function after 177Lu-PSMA Radioligand Therapy: Current Concepts in Imaging and Management","volume":"21","author":"Mahajan","year":"2022","journal-title":"Transl. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.prro.2024.10.014","article-title":"Management of Dry Mouth Toxicity Following 177Lu-PSMA-617 Radioligand Therapy","volume":"15","author":"Pepin","year":"2025","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s00259-024-06677-y","article-title":"[177Lu]Lu-PSMA-617 as First-Line Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Real-World Study","volume":"51","author":"Satapathy","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/RLU.0000000000002833","article-title":"Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients","volume":"45","author":"Yadav","year":"2020","journal-title":"Clin. Nucl. Med."},{"key":"ref_131","first-page":"2187","article-title":"Hematologic Dysfunction and Myeloid Neoplasm Risk in Patients Treated with Lutetium-177 Prostate-Specific Antigen Membrane Therapy","volume":"110","author":"Kusne","year":"2025","journal-title":"Haematologica"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(25)00189-5","article-title":"Health-Related Quality of Life, Pain, and Symptomatic Skeletal Events with [177Lu]Lu-PSMA-617 in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer (PSMAfore): An Open-Label, Randomised, Phase 3 Trial","volume":"26","author":"Fizazi","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Marini, I., Giunta, E.F., Nicolini, S., Grassi, I., Foca, F., Sarnelli, A., Di Iorio, V., Vizza, L., Giani, E., and Celli, M. (2025). Efficacy, Toxicity, and Clinical Outcomes of 177Lu-PSMA-617 Radioligand Therapy at 5.5 GBq per Cycle in Patients with Advanced Castration-Resistant Prostate Cancer: A Prospective, Single Arm, Phase II Study. Eur. J. Nucl. Med. Mol. Imaging, ahead of print.","DOI":"10.1007\/s00259-025-07661-w"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The Diagnosis and Treatment of Prostate Cancer: A Review","volume":"317","author":"Litwin","year":"2017","journal-title":"JAMA"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.euf.2022.08.007","article-title":"Triplet or Doublet Therapy in Metastatic Hormone-Sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-Analysis","volume":"9","author":"Mandel","year":"2023","journal-title":"Eur. Urol. Focus"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"101232","DOI":"10.1016\/j.jpha.2025.101232","article-title":"Novel Hormone Therapies for Advanced Prostate Cancer: Understanding and Countering Drug Resistance","volume":"15","author":"Wang","year":"2025","journal-title":"J. Pharm. Anal."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1200\/JCO.2009.24.1281","article-title":"Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy","volume":"28","author":"Ryan","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.prnil.2016.02.002","article-title":"Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation","volume":"4","author":"Rauch","year":"2016","journal-title":"Prostate Int."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1158\/1078-0432.CCR-11-0728","article-title":"Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants","volume":"17","author":"Mostaghel","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Parker, D., Zambelli, J., Lara, M.K., Wolf, T.H., McDonald, A., Lee, E., Abou-Elkacem, L., Gordon, E.J., and Baum, R.P. (2023). Case Report: Long-Term Complete Response to PSMA-Targeted Radioligand Therapy and Abiraterone in a Metastatic Prostate Cancer Patient. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1192792"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/iju.15657","article-title":"Efficacy of Docetaxel Addition to Next-Generation Androgen Receptor-Axis-Targeted Therapies and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Tumor Volume-Specific Analysis","volume":"32","author":"Chen","year":"2025","journal-title":"Int. J. Urol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e42318","DOI":"10.1097\/MD.0000000000042318","article-title":"Systemic Treatment of Metastatic Castration-Sensitive Prostate Cancer: A Meta-Analysis of Efficacy and Safety","volume":"104","author":"Zhang","year":"2025","journal-title":"Medicine"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41391-020-00280-6","article-title":"Bone Targeted Therapy and Skeletal Related Events in the Era of Enzalutamide and Abiraterone Acetate for Castration Resistant Prostate Cancer with Bone Metastases","volume":"24","author":"McGregor","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e02639","DOI":"10.1002\/cbdv.202502639","article-title":"Steroidal Scaffolds as Anticancer Agents: Evolution, FDA Approvals, Synthetic Derivatives, SAR Profiles, and Translational Perspectives","volume":"22","author":"Gugal","year":"2025","journal-title":"Chem. Biodivers."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e71152","DOI":"10.1096\/fj.202502614R","article-title":"A Dual CYP17A1\/HDAC6 Inhibitor for Targeted Prostate Cancer Therapy","volume":"39","author":"Tran","year":"2025","journal-title":"FASEB J."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/annonc\/mdx759","article-title":"Relationship between patient-reported outcomes and clinical outcomes in metastatic castra-tion-resistant prostate cancer: Post hoc analysis of COU-AA-301 and COU-AA-302","volume":"29","author":"Cella","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1177\/1078155218784716","article-title":"Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancer","volume":"25","author":"Shivji","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S1470-2045(12)70460-6","article-title":"Abiraterone acetate: A hat trick of clinical benefits","volume":"13","author":"Schweizer","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/1756287218786160","article-title":"Abiraterone in chemotherapy-naive patients with metastatic cas-tration-resistant prostate cancer: A systematic review of \u201creal-life\u201d studies","volume":"10","author":"Marchioni","year":"2018","journal-title":"Ther. Adv. Urol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1158\/1078-0432.CCR-14-1961","article-title":"Improvements in radio-graphic progression-free survival stratified by ERG gene status in metastatic castra-tion-resistant prostate cancer patients treated with abiraterone acetate","volume":"21","author":"Attard","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.eururo.2014.02.056","article-title":"Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)","volume":"66","author":"Rathkopf","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus pred-nisone in patients with newly diagnosed high-risk metastatic castration-sensitive pros-tate cancer (LATITUDE): Final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.clon.2017.10.004","article-title":"In-corporating biomarker stratification into STAMPEDE: An adaptive multi-arm, mul-ti-stage trial platform","volume":"29","author":"Gilson","year":"2017","journal-title":"Clin. Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e250023","DOI":"10.57264\/cer-2025-0023","article-title":"Overall survival in patients with metastatic castration-sensitive pros-tate cancer treated with apalutamide versus abiraterone acetate: A head-to-head analy-sis of real-world patients in the USA","volume":"14","author":"Lowentritt","year":"2025","journal-title":"J. Comp. Eff. Res."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Parker, C.C., James, N.D., Brawley, C.D., Clarke, N.W., Ali, A., Amos, C.L., Attard, G., Chowdhury, S., Cook, A., and Cross, W. (2022). Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLoS Med., 19.","DOI":"10.1371\/journal.pmed.1003998"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/14737140.2025.2522981","article-title":"The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer: A stratified meta-analysis based on subgroups of low or high disease volume and reconstructed individual patient data","volume":"25","author":"Zhang","year":"2025","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"FSO436","DOI":"10.2144\/fsoa-2019-0079","article-title":"Prognostic factors for patients treated with abiraterone","volume":"6","author":"Alvim","year":"2019","journal-title":"Future Sci. OA"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.euo.2022.04.007","article-title":"Treatments for metastatic hormone-sensitive prostate cancer: Systematic review, network meta-analysis, and benefit-harm assessment","volume":"5","author":"Menges","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s12325-013-0050-3","article-title":"Abiraterone acetate: Targeting persistent androgen de-pendence in castration-resistant prostate cancer","volume":"30","author":"Harshman","year":"2013","journal-title":"Adv. Ther."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_161","first-page":"e86518","article-title":"Real-world outcomes of upfront abiraterone in metastatic castration-sensitive prostate cancer patients at a tertiary care hospital","volume":"17","author":"Majeed","year":"2025","journal-title":"Cureus"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Achard, V., Ceyz\u00e9riat, K., Tournier, B.B., Frisoni, G.B., Garibotto, V., and Zilli, T. (2021). Biomarkers to evaluate androgen deprivation therapy for prostate cancer and risk of Alzheimer\u2019s disease and neurodegeneration: Old drugs, new concerns. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.734881"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e000049","DOI":"10.1136\/esmoopen-2016-000049","article-title":"Single institution long-term efficacy and safety analysis of abiraterone acetate (AA) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in a named patient programme (NPP)","volume":"1","author":"Rauh","year":"2016","journal-title":"ESMO Open"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e592","DOI":"10.1016\/j.clgc.2019.03.001","article-title":"Cardiovascular and metabolic toxicity of abiraterone in castration-resistant prostate cancer: Post-marketing experience","volume":"17","author":"Tsao","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s11864-024-01215-2","article-title":"Metastatic castration-resistant prostate cancer: Advances in treatment and symptom management","volume":"25","author":"Kulasegaran","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Shaver, A.L., Nikita, N., Sharma, S., Keith, S.W., Zarrabi, K.K., Kelly, W.K., and Lu-Yao, G. (2025). The safety of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: An individual-participant data meta-analysis based on 14 randomized clinical trials. Cancers, 17.","DOI":"10.3390\/cancers17172747"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejca.2020.01.017","article-title":"Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome","volume":"129","author":"Colomba","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","article-title":"The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer","volume":"16","author":"Iacovelli","year":"2018","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41391-024-00873-5","article-title":"Cardiovascular risks of androgen receptor targeted agents in prostate cancer: A systematic review and meta-analysis \u201cPCAN-23-0763R\u201d","volume":"28","author":"Yaxley","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer","volume":"381","author":"Sternberg","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.euf.2023.03.024","article-title":"Triplet or Doublet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Updated Network Meta-Analysis Stratified by Disease Volume","volume":"9","author":"Hoeh","year":"2023","journal-title":"Eur. Urol. Focus"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Yu, Y., Zhang, C., Zhang, J., Zhang, X., and Ouyang, J. (2025). Therapeutic Outcomes of Enzalutamide-Docetaxel Combination versus Docetaxel Monotherapy in Post-Sequential Androgen Receptor Axis-Targeted Therapy Failure Metastatic Castration-Resistant Prostate Cancer. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1608786"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1158\/2767-9764.CRC-25-0254","article-title":"Novel Afro-Caribbean Prostate Cancer Model Reveals Ancestry-Specific Drug Vulnerabilities with Therapeutic Implications for Black Patients","volume":"5","author":"Badal","year":"2025","journal-title":"Cancer Res. Commun."},{"key":"ref_174","first-page":"532","article-title":"PARP inhibitors synergize with abiraterone","volume":"15","author":"Sidaway","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/14796694.2024.2442900","article-title":"Combination niraparib and abiraterone for HRR-altered metastatic castration-resistant prostate cancer","volume":"21","author":"Roberts","year":"2025","journal-title":"Future Oncol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00302","article-title":"Multimodal approach to outcome prediction in metastatic castration-resistant prostate cancer by integrating functional imaging and plasma DNA analysis","volume":"3","author":"Conteduca","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"ref_177","first-page":"1","article-title":"Recent advances in the management of high-risk localized prostate cancer: Local therapy, systemic therapy, and biomarkers to guide treatment decisions","volume":"40","author":"McKay","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Oderda, M., Calleris, G., Iorio, G.C., Simone, G., and Gontero, P. (2025). Radical prostatectomy in multimodal setting: Current role of neoadjuvant and adjuvant hormonal or chemotherapy-based treatments. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32020092"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"100885","DOI":"10.1016\/j.landig.2025.100885","article-title":"External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: A post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE plat-form protocol","volume":"7","author":"Parker","year":"2025","journal-title":"Lancet Digit. Health"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1158\/1078-0432.CCR-11-0815","article-title":"Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response","volume":"17","author":"Ryan","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/annonc\/mdy072","article-title":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: Directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol","volume":"29","author":"Sydes","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: A meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S1470-2045(25)00475-9","article-title":"Abemaciclib plus Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer (CYCLONE 2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"26","author":"Smith","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Czerwi\u0144ska, M., Bilewicz, A., Kruszewski, M., Wegierek-Ciuk, A., and Lankoff, A. (2020). Targeted Radionuclide Therapy of Prostate Cancer\u2014From Basic Research to Clinical Perspectives. Molecules, 25.","DOI":"10.3390\/molecules25071743"},{"key":"ref_185","first-page":"159","article-title":"Recent Development and Future Prospects of Molecular Targeted Therapy in Prostate Cancer","volume":"15","author":"Zhang","year":"2022","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_186","first-page":"100778","article-title":"Emerging Frontiers in Nanomedicine Targeted Therapy for Prostate Cancer","volume":"37","author":"Adekiya","year":"2023","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11864-025-01323-7","article-title":"Advances in Targeted Therapy for Metastatic Prostate Cancer","volume":"26","author":"Grewal","year":"2025","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10549-011-1375-8","article-title":"Biomarkers of PARP inhibitor sensitivity","volume":"127","author":"Turner","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","article-title":"DNA damage repair: Historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"967","DOI":"10.21873\/anticanres.16241","article-title":"Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies","volume":"43","author":"Voutsadakis","year":"2023","journal-title":"Anticancer Res."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","article-title":"RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer","volume":"29","author":"Cruz","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Peng, J., Zhou, J., Liu, G., Kang, P., Tang, X., Luo, Z., and Jiang, Y. (2025). Alterations and cor-relation between DNA damage and repair response and PD-L1 expression in non-small cell lung cancers. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-14065-4"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.2147\/IJN.S139080","article-title":"Targeted Nonviral Gene Therapy in Prostate Cancer","volume":"13","author":"Altwaijry","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Chanhih, N., Laraqui, A., Hassine, S., Ameur, A., Hamedoun, L., El Annaz, H., Abi, R., Tagajdid, M.R., Amine, I.L., and Ennibi, K. (2025). Circulating Tumor DNA as a Biomarker for Precision Medicine in Prostate Cancer: A Systematic Review. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262211049"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Kalender, E., Ekinci, E., Elbo\u011fa, U., and \u015eahin, E. (2025). Efficacy of 177Lu-PSMA-617 Therapy in mCRPC Patients with Liver Metastases: Insights into Survival Outcomes and Predictors of Response. Biomedicines, 13.","DOI":"10.3390\/biomedicines13030569"},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Schweigert, N., Strewinsky, N., K\u00f6hler, D., Lehnert, W., Ekrutt, J., Karimzadeh, A., Klutmann, S., von Amsberg, G., and Sauer, M. (2025). Age-Related Outcomes of [177Lu]Lu-PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer: A Retrospective Analysis. Cancers, 17.","DOI":"10.3390\/cancers17213515"},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Kwon, W.A., and Joung, J.Y. (2025). Neoadjuvant 177Lutetium-PSMA-617 Radioligand Ther-apy for High-Risk Localized Prostate Cancer: Rationale, Early Clinical Evidence, and Future Directions. Cancers, 17.","DOI":"10.20944\/preprints202507.2543.v1"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12020-022-03170-0","article-title":"Radioligand therapy (RLT) as neoadjuvant treatment for inoperable pancreatic neuroendocrine tumors: A literature review","volume":"78","author":"Urso","year":"2022","journal-title":"Endocrine"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.euf.2024.07.016","article-title":"New Drugs for Targeted Radionuclide Therapy in Metastatic Prostate Cancer","volume":"10","author":"Fersing","year":"2024","journal-title":"Eur. Urol. Focus"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1158\/2767-9764.CRC-25-0096","article-title":"Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7-Expressing CRPC Models","volume":"5","author":"Brim","year":"2025","journal-title":"Cancer Res. Commun."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Ban, F., Leblanc, E., Cavga, A.D., Huang, C.F., Flory, M.R., Zhang, F., Chang, M.E.K., Morin, H., Lallous, N., and Singh, K. (2021). Development of an Androgen Re-ceptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer. Cancers, 13.","DOI":"10.3390\/cancers13143488"},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Urso, L., Badrane, I., Manco, L., Castello, A., Lancia, F., Collavino, J., Crestani, A., Castellani, M., Cittanti, C., and Bartolomei, M. (2025). The Role of Radiomics and Arti-ficial Intelligence Applied to Staging PSMA PET in Assessing Prostate Cancer Aggressiveness. J. Clin. Med., 14.","DOI":"10.3390\/jcm14103318"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1158\/0008-5472.CAN-08-3658","article-title":"Adaptive therapy","volume":"69","author":"Gatenby","year":"2009","journal-title":"Cancer Res."},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Kim, T.J., and Koo, K.C. (2020). Current Status and Future Perspectives of Checkpoint Inhibi-tor Immunotherapy for Prostate Cancer: A Comprehensive Review. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155484"},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"F\u00f6rster, S., Niu, Y., Eggers, B., Nokhbehsaim, M., Kramer, F.J., Bekeschus, S., Mus-tea, A., and Stope, M.B. (2023). Modulation of the Tumor-Associated Immuno-Environment by Non-Invasive Physical Plasma. Cancers, 15.","DOI":"10.3390\/cancers15041073"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"e07904","DOI":"10.1002\/advs.202507904","article-title":"Targeting HDAC and PARP Enhances STING-Dependent Antitumor Immun-ity in STING-Deficient Tumor","volume":"12","author":"Mao","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/14712598.2022.2027904","article-title":"Prostate Cancer Immunotherapy","volume":"22","author":"Mitsogiannis","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"Baumgartner, V., Schaer, D., Eberli, D., and Salemi, S. (2023). Targeting Metabolic Vulnerabil-ities to Overcome Prostate Cancer Resistance: Dual Therapy with Apalutamide and Complex I Inhibition. Cancers, 15.","DOI":"10.3390\/cancers15235612"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1158\/0008-5472.CAN-24-0440","article-title":"LX1 Dual Targets AR Variants and AKR1C3 in Advanced Prostate Cancer Therapy","volume":"84","author":"Ning","year":"2024","journal-title":"Cancer Res."},{"key":"ref_211","doi-asserted-by":"crossref","unstructured":"Siltari, A., Syv\u00e4l\u00e4, H., Lou, Y.R., Gao, Y., and Murtola, T.J. (2022). Role of Lipids and Lipid Metabolism in Prostate Cancer Progression and the Tumor\u2019s Immune Environ-ment. Cancers, 14.","DOI":"10.3390\/cancers14174293"},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Kopytov, S.A., Sagitova, G.R., Guschin, D.Y., Egorova, V.S., Zvyagin, A.V., and Rzhevskiy, A.S. (2025). Circulating Tumor DNA in Prostate Cancer: A Dual Perspective on Early Detection and Advanced Disease Management. Cancers, 17.","DOI":"10.3390\/cancers17152589"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/14737159.2019.1664290","article-title":"The current status of the clinical utility of liquid biopsies in cancer","volume":"19","author":"Snow","year":"2019","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s43856-025-00852-4","article-title":"Clinical utility and future perspectives of liquid biopsy in colorectal cancer","volume":"5","author":"Patelli","year":"2025","journal-title":"Commun. Med."},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"van Oostwaard, M.M., van den Bergh, J.P., van de Wouw, A.J., de Jong, M., Janssen-Heijnen, M.L., and Wyers, C.E. (2024). Development of a Multidisciplinary Care Pathway for Fracture Prevention in Men with Prostate Cancer at Initiation of Androgen Deprivation Therapy. Cancers, 16.","DOI":"10.3390\/cancers16152665"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Up-date. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/s44321-025-00282-8","article-title":"New frontiers in prostate cancer treatment from systemic therapy to targeted therapy","volume":"17","author":"Nouruzi","year":"2025","journal-title":"EMBO Mol. Med."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","article-title":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer","volume":"33","author":"Klotz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-Year Outcomes after Monitor-ing, Surgery, or Radiotherapy for Localized Prostate Cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eururo.2013.09.046","article-title":"EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative in-tent\u2014Update 2013","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1113162","article-title":"Radical prostatectomy versus observation for localized prostate cancer","volume":"367","author":"Wilt","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"239.e9","DOI":"10.1016\/j.urolonc.2018.01.004","article-title":"External beam radiotherapy with or without androgen deprivation therapy in elderly patients with high metastatic risk prostate cancer","volume":"36","author":"Bandini","year":"2018","journal-title":"Urol. Oncol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","article-title":"Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomised controlled trial (EORTC trial 22911)","volume":"380","author":"Bolla","year":"2012","journal-title":"Lancet"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in Nonmetastatic, Castra-tion-Resistant Prostate Cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free sur-vival in men with castration-resistant prostate cancer: Results of a phase 3, ran-domised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1002\/cam4.5262","article-title":"Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: A real-world evidence multicenter study","volume":"12","author":"Utriainen","year":"2023","journal-title":"Cancer Med."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3747\/co.v17i5.632","article-title":"Combining radiation therapy and androgen deprivation for localized prostate cancer\u2014A critical review","volume":"17","author":"Cury","year":"2010","journal-title":"Curr. Oncol."},{"key":"ref_232","doi-asserted-by":"crossref","unstructured":"Petersen, S.E., and H\u00f8yer, M. (2021). Androgen Deprivation Therapy Combined with Particle Therapy for Prostate Cancer: A Systematic Review. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.695647"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41391-024-00890-4","article-title":"Salvage therapies for biochemical recurrence after definitive local treatment: A systematic review, meta-analysis, and network meta-analysis","volume":"28","author":"Matsukawa","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"8806","DOI":"10.1038\/s41467-025-64042-5","article-title":"Elucidating Molecularly Stratified Single Agent, and Combination, Therapeutic Strategies Targeting MCL1 for Lethal Prostate Cancer","volume":"16","author":"Westaby","year":"2025","journal-title":"Nat. Commun."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/2\/685\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:11:21Z","timestamp":1768543881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/2\/685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":234,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["jcm15020685"],"URL":"https:\/\/doi.org\/10.3390\/jcm15020685","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]}}}